Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada

被引：47

作者：

Blackhouse G. ^{[1
,2
]}

Gaebel K. ^{[1
,3
]}

Xie F. ^{[1
,2
,3
]}

Campbell K. ^{[1
,2
]}

Assasi N. ^{[1
,2
]}

Tarride J. ^{[1
,2
,3
]}

O'Reilly D. ^{[1
,2
,3
]}

Chalk C. ^{[4
]}

Levine M. ^{[2
,3
]}

Goeree R. ^{[1
,2
,3
]}

机构：

[1] PATH Research Institute, McMaster University, Hamilton, ON

[2] Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON

[3] Centre for Evaluation of Medicines, St. Joseph's Healthcare, Hamilton, ON

[4] Department of Neurology and Neurosurgery, McGill University, Montréal, QC

来源：

Cost Effectiveness and Resource Allocation | / 8卷 / 1期

关键词：

Corticosteroid Treatment; Quality Adjust Life Year; Probabilistic Sensitivity Analysis; Chronic Inflammatory Demyelinating Polyneuropathy; IVIG Treatment;

D O I：

10.1186/1478-7547-8-14

中图分类号：

学科分类号：

摘要：

Objectives: Intravenous immunoglobulin (IVIG) has demonstrated improvement in chronic inflammatory demyelinating polyneuropathy (CIDP) patients in placebo controlled trials. However, IVIG is also much more expensive than alternative treatments such as corticosteroids. The objective of the paper is to evaluate, from a Canadian perspective, the cost-effectiveness of IVIG compared to corticosteroid treatment of CIDP.Methods: A markov model was used to evaluate the costs and QALYs for IVIG and corticosteroids over 5 years of treatment for CIDP. Patients initially responding to IVIG could remain a responder or relapse every 12 week model cycle. Non-responding IVIG patients were assumed to be switched to corticosteroids. Patients on corticosteroids were at risk of a number of adverse events (fracture, diabetes, glaucoma, cataract, serious infection) in each cycle.Results: Over the 5 year time horizon, the model estimated the incremental costs and QALYs of IVIG treatment compared to corticosteroid treatment to be $124,065 and 0.177 respectively. The incremental cost per QALY gained of IVIG was estimated to be $687,287. The cost per QALY of IVIG was sensitive to the assumptions regarding frequency and dosing of maintenance IVIG.Conclusions: Based on common willingness to pay thresholds, IVIG would not be perceived as a cost effective treatment for CIDP. © 2010 Blackhouse et al; licensee BioMed Central Ltd.

引用

共 41 条

[1]

van Schaik I., Van den Bergh P., de Haan R., Vermeulen M., Intravenous immunoglobulin for multifocal motor neuropathy, Cochrane Database Syst Rev, 2, (2006)

[2]

Lewis R.A., Chronic inflammatory demyelinating polyneuropathy, Neurol Clin, 25, pp. 71-87, (2007)

[3]

Lunn M.P., Manji H., Choudhary P.P., Hughes R.A., Thomas P.K., Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England, J Neurol Neurosurg Psychiatry, 66, pp. 677-680, (1999)

[4]

McLeod J.G., Pollard J.D., Macaskill P., Mohamed A., Spring P., Khurana V., Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia, Ann Neurol, 46, pp. 910-913, (1999)

[5]

GBS CIDP guide, (2005)

[6]

Dyck P.J., O'Brien P.C., Oviatt K.F., Dinapoli R.P., Daube J.R., Bartleson J.D., Et al., Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment, Ann Neurol, 11, pp. 136-141, (1982)

[7]

Merkies I., Bril V., Dalakas M., Deng C., Donofrio P., Hanna K., Quality-of-Life (QoL) Improvements with Immune Globulin Intravenous, 10% Caprylate/Chromatography Purified (IGIV-C) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) [abstract M-3], 133rd Annual Meeting of the American Neurological Association, (2008)

[8]

Dyck P.J., Intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy and in neuropathy associated with IgM monoclonal gammopathy of unknown significance, Neurology, 40, pp. 327-328, (1990)

[9]

Hahn A.F., Bolton C.F., Zochodne D., Feasby T.E., Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study, Brain, 119, pp. 1067-1077, (1996)

[10]

(2008)

← 1 2 3 4 5 →